Detecting all 207 types of human cancer with 97.8% accuracy in 24 hours—before symptoms appear. Positioned for a 975,000-patient government pilot program launching Q2 2026.
Our ambition is to become a household name within 3 to 5 years. We aim to build a $25 billion company, but the real goal is saving lives by catching cancer before it catches you.
— Life Sciences Review Cover Story, 2025
The Opportunity
Scalable investment structure—more locations = greater pilot allocation and returns
Tier 1
2 licensed locations
32% pilot allocation (8K tests/mo)
Tier 2 — Recommended
4 licensed locations
64% pilot allocation (16K tests/mo)
Tier 3
6+ licensed locations
80%+ pilot allocation
Conservative projections based on government pilot participation
Tier 1 Investment
2 Locations
Conservative Return
12-18 months
Upside Potential
Full pilot scale
Flexible Investment Options: Interested in a smaller initial investment with rights to participate in future rounds? We're open to discussions. Contact us to explore seed-stage opportunities starting at $250K.
Unit Economics
Strong margins in both direct-to-market and government pilot programs
Currently Active
Laboratory services to physicians & hospitals
Net margin per test (48%)
Q2 2026 Target Launch
975,000 patient federal screening study
Net margin per test (63%)
Why Invest
A protected downside with significant upside through early cancer detection leadership
Named "Early Cancer Detection Testing Company of the Year 2025" by Life Sciences Review. Proprietary FISH-based DNA probe technology with 97.8% accuracy detecting 207 cancer types—validated across 35+ years of clinical use.
Selected laboratory partner for 975,000-patient federal screening study. 4,000 tests/month allocation per licensed location—more locations = greater share of the study and higher returns. Post-study recurring revenue from high-risk patient monitoring.
48% margin on direct-to-market tests ($288 net) and 63% margin on government pilot ($542 net). Recurring revenue model: 15% of patients test high-risk and retest 6Ă— annually. Reflex testing adds 10-15% additional revenue.
MCED market projected at $50B+ by 2030. Cancer is now the leading cause of death in the U.S. with 45% of cancers lacking standard screening. TruView OncoScreen® addresses critical unmet need with accessible, affordable testing.
Early detection reduces treatment costs by 20Ă— ($1M-$1.5M late-stage vs $20K-$50K early-stage). Value-based billing model aligns incentives with payers. Strong Medicare/Medicaid support for preventive screening.
CLIA-certified, COLA-accredited laboratory with perfect inspection score. 2,400+ partner collection locations nationwide. Established CPT codes for insurance reimbursement. Scalable capacity for Phase 2 volume.
Q2 2026 Target Launch
Federal screening study to identify and monitor high-risk cancer patients using TruView OncoScreen® platform
Phase 1 of Study
patients/month Ă— 3 months
Phase 2 of Study
patients/month Ă— 3 months
Total Study
patients over 6 months
Tier 1: $1.5M Investment
target return
2 locations (32% allocation)
12-18 month timeline
3.3x+ multiple
Tier 2: $3M Investment
target return
4 locations (64% allocation)
12-18 month timeline
3.3x+ multiple
Tier 3: $5M+ Investment
target return
6+ locations (80%+ allocation)
12-18 month timeline
4x+ multiple
Even if the government pilot doesn't proceed, the direct-to-market business presents a compelling standalone opportunity.
Market Disruption Potential: TruView OncoScreen® can replace existing single-cancer screening tests like Cologuard, Shield, and Cancerguard. We detect 4× more cancer types with higher accuracy and same-day results. With 70% of annual cancer deaths linked to tumors with no current screening method, we're addressing a massive unmet need.
The Science
Breakthrough molecular analysis delivering industry-leading accuracy and speed
TruView OncoScreen® detects oncosomes—microscopic extracellular vesicles released by active cancer cells into the bloodstream. These biomarkers are present before tumors are large enough to detect via imaging, enabling true early detection at Stage -1.
Our proprietary DNA probe uses FISH (Fluorescence In Situ Hybridization), a diagnostic method trusted for over 35 years. The test provides a quantitative Oncosome Count that guides clinical decision-making and enables real-time treatment monitoring.
Fastest turnaround in the industry
Comprehensive screening from one draw
Simple blood draw, no radiation
Track therapy effectiveness in real-time
| Test | Cancers | Accuracy | Results | Cost |
|---|---|---|---|---|
| TruView OncoScreen® | 207 types | 97.8% | 24 hours | $895 |
| Cancerguard (Exact Sciences) | 50+ types | 64% | 2 weeks | $689 |
| Galleri (Grail) | ~50 types | 51% | 2-3 weeks | $949 |
| Shield (Guardant) | 1 (colorectal only) | 83% | Days | $895 |
| Cologuard (stool test) | 1 (colorectal only) | 92% | Days | Covered |
TruView OncoScreen detects 4Ă— more cancer types with higher accuracy and same-day results.
Leadership
Experienced operators with deep expertise in diagnostics and healthcare technology
Founder & General Managing Partner
Healthcare technology entrepreneur with deep expertise in diagnostic laboratory operations, Medicare billing, and healthcare technology. Founder of OnParo LIS and Precision DX Group. Extensive network of 9,000+ healthcare contacts nationwide.
Interested in learning more about this investment opportunity? Contact us to receive the complete DD package including financial models, pilot program documentation, and clinical validation data.